ATE370123T1 - 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen - Google Patents

3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen

Info

Publication number
ATE370123T1
ATE370123T1 AT02794031T AT02794031T ATE370123T1 AT E370123 T1 ATE370123 T1 AT E370123T1 AT 02794031 T AT02794031 T AT 02794031T AT 02794031 T AT02794031 T AT 02794031T AT E370123 T1 ATE370123 T1 AT E370123T1
Authority
AT
Austria
Prior art keywords
cyanocinolines
egf
inhibitors
her2 kinases
her2
Prior art date
Application number
AT02794031T
Other languages
English (en)
Inventor
Allan Wissner
Hwei-Ru Tsou
Middleton Floyd
Bernard Johnson
Elsebe Overbeek-Klumpers
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE370123T1 publication Critical patent/ATE370123T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02794031T 2001-11-27 2002-11-26 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen ATE370123T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33356801P 2001-11-27 2001-11-27

Publications (1)

Publication Number Publication Date
ATE370123T1 true ATE370123T1 (de) 2007-09-15

Family

ID=23303345

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02794031T ATE370123T1 (de) 2001-11-27 2002-11-26 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen

Country Status (24)

Country Link
US (1) US6821988B2 (de)
EP (1) EP1448531B1 (de)
JP (1) JP2005514384A (de)
KR (1) KR20050044599A (de)
CN (1) CN1659145A (de)
AR (1) AR037438A1 (de)
AT (1) ATE370123T1 (de)
AU (1) AU2002359489B2 (de)
BR (1) BR0214485A (de)
CA (1) CA2467573A1 (de)
CO (1) CO5580828A2 (de)
DE (1) DE60221886D1 (de)
EC (1) ECSP045122A (de)
HU (1) HUP0402228A2 (de)
IL (1) IL161921A0 (de)
MX (1) MXPA04004969A (de)
NO (1) NO20042634L (de)
NZ (1) NZ533118A (de)
PL (1) PL370137A1 (de)
RU (1) RU2309150C2 (de)
TW (1) TW200300348A (de)
UA (1) UA77469C2 (de)
WO (1) WO2003050090A1 (de)
ZA (1) ZA200405025B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
EP1521747B1 (de) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Modulatoren von rezeptor-typ-kinase und anwendungsverfahren
KR20060054412A (ko) * 2003-08-01 2006-05-22 와이어쓰 홀딩스 코포레이션 암 치료 및 억제용 표피 성장인자 수용체 키나제 억제제와세포독성제의 배합물 용도
US7365203B2 (en) * 2003-09-15 2008-04-29 Wyeth Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1670473A1 (de) * 2003-09-15 2006-06-21 Wyeth a Corporation of the State of Delaware Substituierte chinoline als proteintyrosinkinaseinhibitoren
EP2210607B1 (de) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamid zur Behandlung von Krebs
US7781591B2 (en) 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
BRPI0515012A (pt) 2004-08-13 2008-07-01 Genentech Inc substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
TW200616612A (en) * 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US7624279B2 (en) * 2005-06-29 2009-11-24 Lenovo Singapore Pte. Ltd. System and method for secure O.S. boot from password-protected HDD
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
EP3488866A1 (de) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastische kombinationen mit mtor-inhibitor, herceptin und/oder hki-272
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
MX2008015802A (es) * 2006-06-13 2009-01-09 Wyeth Corp 3-cianopiridinas sustituidas como inhibidores de proteina quinasa.
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (de) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastische kombinationen aus neratinib und capecitabin
ITMI20082336A1 (it) * 2008-12-29 2010-06-30 Univ Parma Composti inibitori irreversibili di egfr con attivita' antiproliferativa
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
EP2498751B1 (de) 2009-11-09 2019-04-03 Wyeth LLC Umhüllte wirkstoffspäroide und verwendung davon zur verhinderung oder reduzierung von erbrechen und diarrhöe
US9187458B2 (en) * 2010-06-09 2015-11-17 Tianjin Hemay Bio-Tech Co., Ltd. Cyanoquinoline derivatives
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
EA025451B1 (ru) * 2010-08-26 2016-12-30 Симфони Эволюшн, Инк. Модулятор киназы рецепторного типа и способы лечения поликистозной болезни почек
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
CN103214489B (zh) * 2013-02-25 2016-10-26 中国人民解放军第二军医大学 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103304494B (zh) * 2013-06-20 2015-05-27 河北大学 茚(1,2-b)喹喔啉-11-酮肟衍生物及其制备方法和用途
EP3187491A4 (de) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. Hochreines chinolinderivat und verfahren zur herstellung davon
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
US10774068B2 (en) * 2015-06-25 2020-09-15 The Scripps Research Institute Composition and methods for inhibiting mammalian sterile 20-like kinase 1
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
WO2017117474A1 (en) * 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
CN115057861A (zh) * 2016-03-01 2022-09-16 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
ES2962961T3 (es) 2017-07-28 2024-03-22 Yuhan Corp Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo
CN110452232A (zh) * 2019-09-17 2019-11-15 北京振东光明药物研究院有限公司 阿法替尼杂质化合物及其制备方法与应用
CN111995618B (zh) * 2020-09-02 2021-06-11 重庆医科大学 一种来那替尼杂质g的制备方法
CN111943933B (zh) * 2020-09-02 2021-05-28 重庆医科大学 一种来那替尼杂质d的制备方法
EP4682143A1 (de) * 2023-03-10 2026-01-21 Convalife Pharmaceuticals Co., Ltd. Pharmazeutische zusammensetzung mit egfr-hemmer sowie herstellungsverfahren dafür und verwendung davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2242425C (en) * 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235740B1 (en) * 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
CZ303899B6 (cs) 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
HU230728B1 (hu) * 1998-09-29 2017-12-28 Wyeth Holdings Llc Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
BR0016878A (pt) * 1999-12-29 2002-10-08 Wyeth Corp Inibidores tricìclicos de cinases protéicas
US7067532B2 (en) * 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents

Also Published As

Publication number Publication date
KR20050044599A (ko) 2005-05-12
ECSP045122A (es) 2004-07-23
US6821988B2 (en) 2004-11-23
NO20042634L (no) 2004-06-23
DE60221886D1 (de) 2007-09-27
UA77469C2 (en) 2006-12-15
HUP0402228A2 (hu) 2005-02-28
WO2003050090A1 (en) 2003-06-19
RU2004119414A (ru) 2006-02-27
US20030149056A1 (en) 2003-08-07
AU2002359489A1 (en) 2003-06-23
CN1659145A (zh) 2005-08-24
CO5580828A2 (es) 2005-11-30
PL370137A1 (en) 2005-05-16
NZ533118A (en) 2006-07-28
AR037438A1 (es) 2004-11-10
RU2309150C2 (ru) 2007-10-27
MXPA04004969A (es) 2004-08-11
EP1448531B1 (de) 2007-08-15
TW200300348A (en) 2003-06-01
BR0214485A (pt) 2004-09-14
EP1448531A1 (de) 2004-08-25
ZA200405025B (en) 2006-12-27
IL161921A0 (en) 2005-11-20
JP2005514384A (ja) 2005-05-19
AU2002359489B2 (en) 2008-10-30
CA2467573A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
DE60221886D1 (de) 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen
ATE414699T1 (de) Inhibitoren von tyrosinkinasen
ATE370938T1 (de) Pro-pharmakon von cox-2-inhibitoren
DE60021423D1 (de) 4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DE60214701D1 (de) Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
ATE323072T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
ATE309996T1 (de) Chinolinonderivate als tyrosin-kinase inhibitoren
DE60211601D1 (de) Bereitstellung von positionsabhängigen Inhalten
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
EP1534268A4 (de) Tyrosin-kinase-hemmer
ATE395346T1 (de) Chinazolinderivate als tyrosinkinaseinhibitoren
ATE431346T1 (de) Substituierte naphthylindolderivate und ihre verwendung als plasminogen aktivator inhibitor (pai-1) inhibitoren
ATE323081T1 (de) N-formylhydroxylamin verbindungen als inhibitoren von pdf
ATE453624T1 (de) Kristallform von lercanipidin-hydrochlorid zur verwendung als antihypertensives mittel
ATE264328T1 (de) Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
DK1432417T3 (da) Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer
EP1651599A4 (de) Tyrosin-kinase-hemmer
DE60302152D1 (de) Diaminothiazole und ihre anwendung als cdk4 inhibitoren
EP1496897A4 (de) Tyrosinkinase-hemmer
DE60203120D1 (de) Imidazopyridinone als p38 map kinase inhibitoren
ATE387451T1 (de) Chinazolinderivate als src- tyrosinkinaseinhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties